Limitless biotech mots-c 5 mg | Supports Mitochondrial Health

MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA-c) represents a pioneering discovery in the field of endocrinology and mitochondrial medicine. As a 16-amino acid peptide encoded within the mitochondrial genome rather than the cell’s nucleus, it functions as a “mitokine”—a systemic signaling molecule that facilitates essential communication between mitochondria and the nuclear genome. This unique metabolic regulator is increasingly recognized for its influence on systemic homeostasis, particularly in how the body adapts to metabolic stress and energy demands.

Mitochondrial Signaling and the AMPK Pathway

The biological significance of MOTS-c lies in its role in retrograde signaling, where it acts as a messenger from the mitochondria to the nucleus to coordinate cellular responses. Its primary mechanism involves the Folate-AICAR-AMPK axis. Upon translocation to the nucleus, MOTS-c inhibits the folate cycle, leading to an intracellular accumulation of AICAR. This accumulation triggers the activation of AMP-activated protein kinase (AMPK), often described as the body’s metabolic master switch. Activation of the AMPK pathway mimics many of the beneficial effects of physical exercise, such as increasing glucose uptake in skeletal muscles and promoting the oxidation of fatty acids.

Scientific interest in MOTS-c has been bolstered by its observed effects in preliminary research models. Rodent studies have demonstrated that MOTS-c can prevent weight gain under high-fat dietary conditions and significantly enhance physical endurance by rejuvenating muscle metabolism. In humans, research is currently in the observational and pilot stages. Genetic studies of centenarians have identified specific polymorphisms in the MOTS-c sequence associated with exceptional longevity, while lower levels of circulating MOTS-c have been correlated with metabolic challenges and aging. It is important to note that while animal data is robust, human application remains a subject of ongoing investigation into its role as a regulator of metabolic homeostasis.

Physiological Benefits of MOTS-c

Usage and Reconstitution Standards

In a research context, MOTS-c is typically provided as a lyophilized (freeze-dried) powder to ensure stability during transport and storage. Preparation involves reconstitution with Bacteriostatic Water (0.9% benzyl alcohol). Once the solution is prepared, the peptide is highly sensitive and must be stored in a refrigerated environment at 2-8°C to maintain its bioactive integrity. Experimental protocols often describe subcutaneous administration, typically in the abdominal or thigh area. Common research cycles involving this peptide often consist of a 5 mg dose administered once or twice weekly over a period of 4 to 8 weeks, though these are strictly investigational parameters and do not constitute clinical recommendations.

Safety and Regulatory Status

MOTS-c is currently categorized as a Research Use Only (RUO) compound and is not approved by the FDA for human use. Users must be aware of potential metabolic interactions, particularly with glucose-lowering agents. There is a high risk of additive interaction when combined with Metformin or insulin, which could lead to hypoglycemia. Furthermore, because MOTS-c influences metabolic signaling pathways that promote cell survival, there is a theoretical caution for individuals with a history of malignancy. Reported side effects in research settings include localized injection site reactions such as redness or itching, as well as transient metabolic fatigue during the initial adjustment period. Additionally, MOTS-c is listed on the WADA prohibited list under S4 Hormone and Metabolic Modulators; it is not legal for use in competitive sports.

Frequently Asked Questions